Bristol-Myers Squibb

BMY

Market cap $100B

Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches.

Bristol Myers has struggled to generate growth in recent years. Its high debt load has come down but remains a burden for the business.

Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project net gains of 18.44% to 29.95% for the top ten BBB Dogs by November 2026, with an average estimated gain of 22.01%. Stocks are considered 'dogs' when their reliable dividends and lower prices result in higher yields; eight of the top ten are already at ideal pricing levels.

GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.

Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.

Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare Conference.

Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma.

Bayer AG (OTC: BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.